Perrigo Company plc (NYSE:PRGO – Get Free Report) EVP Abigail Lennox bought 1,255 shares of the firm’s stock in a transaction on Monday, September 8th. The shares were purchased at an average cost of $22.41 per share, with a total value of $28,124.55. Following the completion of the transaction, the executive vice president owned 1,255 shares in the company, valued at $28,124.55. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Perrigo Trading Up 1.8%
Shares of NYSE PRGO opened at $22.52 on Friday. The firm has a market cap of $3.10 billion, a PE ratio of -38.82 and a beta of 0.48. The company has a quick ratio of 1.24, a current ratio of 2.32 and a debt-to-equity ratio of 0.81. Perrigo Company plc has a twelve month low of $21.03 and a twelve month high of $30.93. The business has a fifty day simple moving average of $25.10 and a two-hundred day simple moving average of $26.07.
Perrigo (NYSE:PRGO – Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.57 EPS for the quarter, missing the consensus estimate of $0.59 by ($0.02). The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.08 billion. Perrigo had a positive return on equity of 9.09% and a negative net margin of 1.86%.The company’s revenue was down .9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.53 earnings per share. Analysts expect that Perrigo Company plc will post 2.56 earnings per share for the current fiscal year.
Perrigo Dividend Announcement
Analysts Set New Price Targets
Several research analysts have recently commented on PRGO shares. Wall Street Zen raised Perrigo from a “hold” rating to a “buy” rating in a research report on Friday, September 5th. JPMorgan Chase & Co. reduced their price target on Perrigo from $38.00 to $35.00 and set an “overweight” rating for the company in a research report on Thursday, August 7th. Finally, Canaccord Genuity Group reduced their target price on Perrigo from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Perrigo presently has an average rating of “Hold” and a consensus target price of $33.00.
Get Our Latest Stock Analysis on Perrigo
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in PRGO. Geneos Wealth Management Inc. grew its stake in Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares during the last quarter. Huntington National Bank grew its stake in Perrigo by 237.8% during the 2nd quarter. Huntington National Bank now owns 1,054 shares of the company’s stock valued at $28,000 after purchasing an additional 742 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in Perrigo by 54.6% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,201 shares of the company’s stock valued at $32,000 after purchasing an additional 424 shares during the last quarter. Hantz Financial Services Inc. grew its stake in Perrigo by 101.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 1,234 shares of the company’s stock valued at $33,000 after purchasing an additional 620 shares during the last quarter. Finally, Picton Mahoney Asset Management purchased a new stake in Perrigo during the 1st quarter valued at about $42,000. 95.91% of the stock is owned by institutional investors and hedge funds.
About Perrigo
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Recommended Stories
- Five stocks we like better than Perrigo
- How to Invest in Insurance Companies: A Guide
- High-Flyers Near Resistance: 3 Stocks to Watch for a Dip
- Why Are These Companies Considered Blue Chips?
- Seagate Technology Leads S&P 500: What’s Behind Its 120% Gain?
- Using the MarketBeat Dividend Tax Calculator
- Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.